Long-term risk for subsequent leukemia after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study

Blood

Volumn 117, Issue 23, 2011, Pages 6315-6318

  Nottage, Kerri ^a   Lanctot, Jennifer ^a   Li, Zhenghong ^a   Neglia, Joseph P ^b   Bhatia, Smita ^c   Hammond, Sue ^d   Leisenring, Wendy ^e   Meadows, Anna ^f   Srivastava, Deokumar ^a   Robison, Leslie L ^a   Armstrong, Gregory T ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CANCER THERAPY; CHILDHOOD CANCER; CHROMOSOME 7Q; CHROMOSOME DELETION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK FACTOR;

EID: 79959402991     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-335158     Document Type: Article

References (25)

1. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2007.
2. Meadows A, Friedman D, Neglia J, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356-2362.
3. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-1095.
4. Bhatia S, Yasui Y, Robison L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386-4394. (Pubitemid 46621816)
5. Pedersen-Bjergaard J, Philip P, Larsen S, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76(6):1083-1091. (Pubitemid 20318150)
6. Rowley J, Golomb H, Vardiman J. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981;58(4):759-767. (Pubitemid 11015833)
7. Pui C, Behm F, Raimondi S, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321(3):136-142. (Pubitemid 19180676)
8. Pui C. Therapy-related myeloid leukaemia. Lancet. 1990;336(8723):1130- 1131. (Pubitemid 20368781)
9. Ratain M, Rowley J. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992;3(2):107-111.
10. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995;13(7):1557-1563.
11. Hijiya N, Ness K, Ribeiro R, Hudson M. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115(1):23-35.
12. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:453-459.
13. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002; 38(4):229-239. (Pubitemid 34258414)
14. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009; 27(14):2308-2318.
15. Bhatia S, Robison L, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334(12): 745-751. (Pubitemid 26089355)
16. Smith M, Rubinstein L, Anderson J, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17(2):569-577. (Pubitemid 29075244)
17. Pui C, Hancock M, Raimondi S, et al. Myeloid neoplasia in children treated for solid tumours. Lancet. 1990;336(8712):417-421. (Pubitemid 20252446)
18. Pui C, Ribeiro R, Hancock M, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325(24):1682-1687.
19. Tucker M, Coleman C, Cox R, Varghese A, Rosenberg S. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988; 318(2):76-81. (Pubitemid 18029298)
20. van Leeuwen F, Klokman W, Veer M, et al. Longterm risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-497. (Pubitemid 30078530)
21. Brusamolino E, Anselmo A, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica. 1998;83(9):812-823. (Pubitemid 28496170)
22. Blayney D, Longo D, Young R, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med. 1987;316(12):710-714. (Pubitemid 17036476)
23. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors: III. Leukemia, lymphoma and multiple myeloma, 1950- 1987. Radiat Res. 1994;137(suppl 2):S68-S97. (Pubitemid 24060247)
24. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res. 2000;6(10):4091-4095.
25. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009; 27(5):791-798.